Ribon Therapeutics is a clinical stage biopharmaceutical company that specializes in the development of novel small molecules targeting stress support pathways in cancer and inflammation. The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, clinics, and other healthcare providers.

The company's business model revolves around its proprietary BEACON+ platform. This platform is designed to explore the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics. In simple terms, Ribon Therapeutics uses this platform to create new drugs that can target and disrupt the processes that cause cancer and inflammation.

One of the company's leading products is RBN-2397, a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7. This drug is being developed for the treatment of solid tumors. The company has recently started a Phase 1 clinical study with another product, RBN-3143, in patients with moderate-to-severe atopic dermatitis.

Ribon Therapeutics generates revenue through the sale of its developed drugs to healthcare providers. The company also potentially earns income from partnerships with other pharmaceutical companies, research grants, and licensing agreements.

Keywords: Biopharmaceutical, Cancer, Inflammation, BEACON+ platform, NAD+-utilizing enzymes, Small molecule therapeutics, RBN-2397, PARP7 inhibitor, Solid tumors, Atopic dermatitis.